Coherus BioSciences, a commercial-stage biopharmaceutical company, agreed to acquire Surface Oncology, an immuno-oncology company, for $65m. “This transaction is well-timed, as it coincides with the accelerating growth of our biosimilar revenues driven by the launch of CIMERLI® and near-term launch of YUSIMRY®. With the agreement to acquire Surface and the expected near-term approval of toripalimab, Coherus is positioned to become one of the very few I-O companies with demonstrated commercial expertise, significant product revenues, and unique, competitively positioned R&D programs addressing critical unmet medical needs,” Denny Lanfear, Coherus Chairman and CEO.